Record Revenue Growth
Revenue was $481 million for Q4 and $1.5 billion for the 2024 fiscal year, representing year-over-year growth of 95% for Q4 and 69% for the fiscal year.
Subscriber Growth
Total subscribers increased 45% to over 2.2 million in Q4, with over 55% subscribing to at least one personalized solution.
Expansion of Personalized Treatments
Unique form factors and personalized dosages are unlocking growth, with subscribers in men's and women's dermatology growing over 55% and 100% year-over-year, respectively.
First Full Year of GAAP Profitability
Net income was $26 million in Q4 and $126 million for the full year, marking the company's first full year of GAAP profitability.
Strong Cash Flow
The company generated nearly $60 million of free cash flow in Q4, totaling nearly $200 million for the year.
Innovative Acquisitions
Acquired whole body lab testing facilities and a peptide facility to enhance personalization and innovation in health care services.